Headquartered in Lexington, MA Fiscal year ends December NASDAQ: CRIS curis.com
Curis, Inc. is a clinical-stage biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 and FLT3 inhibitor. The company's pipeline centers on emavusertib across multiple oncology indications including relapsed/refractory primary CNS lymphoma (PCNSL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), and solid tumors such as gastric, esophageal, and pancreatic cancers. Emavusertib is being evaluated in combination with BTK inhibitors (ibrutinib and zanubrutinib) in hematologic malignancies and with chemotherapy/immunotherapy regimens in solid tumors. The drug has received Orphan Drug Designation from the FDA for PCNSL, AML, and MDS and from the European Commission for PCNSL. Curis holds its rights to emavusertib through a 2015 collaboration with Aurigene Discovery Technologies Limited. The company previously generated royalty revenue from Genentech and Roche's sales of Erivedge but sold that royalty stream in late 2025, making it a pre-revenue company dependent on external financing to fund its clinical programs. Curis trades on the NASDAQ Capital Market under the ticker CRIS. Updated
Thursday's top analyst upgrades and downgrades included AllianceBernstein, AMD, Cisco, eHealth, iHeart Media, Intel, Playtika, ViacomCBS and Williams-Sonoma.
Curis shares are on the run again. This time it’s due to a secondary offering.
Chris Lange Curis has announced preliminary data from its ongoing early-stage study in patients with acute myeloid leukemia or high-risk myelodysplastic syndromes.
Chris Lange Curis, Inc. is a clinical-stage biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 and FLT3 inhibitor.
The Wall Street consensus 12-month price target for CRIS is $42.67.
